Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 20 of 174 for:    "Heart Disease" | "Heparin"

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism (SAFE-LYSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03988842
Recruitment Status : Not yet recruiting
First Posted : June 18, 2019
Last Update Posted : June 18, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
Victor Tapson, MD, Cedars-Sinai Medical Center

No Study Results Posted on for this Study
Recruitment Status : Not yet recruiting
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2022